Wisconsin Alumni Research Foundation

Cynata Therapeutics Limited

Other

Igor I Slukvin

James A Thomson

Maksym A Vodyanyk

Maryna E Gumenyuk

Akhilesh Kumar

Gene Ichiro Uenishi

Irina Elcheva

William Leo Murphy

Jue Zhang

Zhonggang Hou

Michael P Schwartz

Nicholas E Propson

Derek J Hei

Kran Suknuntha

Kyung-Dal Choi

Diana Drier

Junying Yu

Anna Huttenlocher

David Alfred Bennin

Vera Sergeyevna Brok Volchanskaya

Gene Uenishi

Lucas Klemm

Mi Ae Park

Gene I Uenishi

Brian McIntosh

Maksym Vodyanyk

Derek Hei

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Derivation of human microglia from pluripotent stem cells

The present invention provides methods of producing in vitro derived neutrophils or macrophages in xenogen- and serum-free conditions from pluripotent stem cells and in vitro derived populations of neutrophils and macrophages. Methods of treatment using in vitro derived neutrophils or macrophages are also contemplated.

Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2

The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.

Generating vasculogenic cell populations

The invention relates to a method for detecting residual, undifferentiated pluripotent stem cells (PSCs) in a culture of cells differentiated from PSCs, the method comprising:

Pluripotent stem cell assay

Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.

Induction of hemogenic endothelium from pluripotent stem cells by forced expression of transcription factors

The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK and NOTCH signaling at the mesodermal stage of differentiation.

Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways

The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.

Colony forming medium and use thereof

This invention discloses a method for the induction of arterial-type of hemogenic endothelium.

Method for the induction of arterial-type of hemogenic endothelium from hPSCS

Methods and compositions of erythroid cells that produce adult &#x3b2;-hemoglobin, generated by culturing CD31+, CD31+/CD34+ or CD34+ cells from embryonic stem cells under serum-free culture conditions.

Erythroid cells producing adult-type beta-hemoglobin generated from human embryonic stem cells

A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFR&#x3b1;, CD31, CD235a, CD73, CD43, and CD41a.

Angiohematopoietic progenitor cells

Methods and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.

Growing community of inventors

Verona, WI, United States of America

Igor I Slukvin